Skip to main content
TipRanks
Go Ultimate75% OFF

Compare ALK-abello (4AJ0) vs. Competitors

2 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:4AJ0ALK-abelloEUR 33.20EUR 7.40B40.7217.81%―Unlock the DE:4AJ0 analyst price target with TipRanks PremiumDE:4AJ0Unlock the DE:4AJ0 top-analyst price target with TipRanks Premium
AKBLFALK-abello$36.67$8.15B40.725.53%―Unlock the AKBLF analyst price target with TipRanks PremiumDE:4AJ0 vs AKBLFUnlock the AKBLF top-analyst price target with TipRanks Premium
INOInovio Pharmaceuticals$1.43$267.85M-1.80-26.67%Strong BuyUnlock the INO analyst price target with TipRanks PremiumDE:4AJ0 vs INOUnlock the INO top-analyst price target with TipRanks Premium
ACRSAclaris Therapeutics$3.92$621.76M-6.7668.97%Strong BuyUnlock the ACRS analyst price target with TipRanks PremiumDE:4AJ0 vs ACRSUnlock the ACRS top-analyst price target with TipRanks Premium
EBSEmergent Biosolutions$5.79$297.69M-1.15-43.90%HoldUnlock the EBS analyst price target with TipRanks PremiumDE:4AJ0 vs EBSUnlock the EBS top-analyst price target with TipRanks Premium
NVSNovartis$160.50$292.45B30.7321.67%Moderate BuyUnlock the NVS analyst price target with TipRanks PremiumDE:4AJ0 vs NVSUnlock the NVS top-analyst price target with TipRanks Premium
BMYBristol-Myers Squibb$63.43$129.66B14.0330.43%Moderate BuyUnlock the BMY analyst price target with TipRanks PremiumDE:4AJ0 vs BMYUnlock the BMY top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:4AJ0ALK-abello33.202.508.14%
AKBLFALK-abello36.670.701.94%
INOInovio Pharmaceuticals1.43-0.55-27.78%
ACRSAclaris Therapeutics3.921.4760.00%
EBSEmergent Biosolutions5.79-4.31-42.67%
NVSNovartis160.5031.4824.40%
BMYBristol-Myers Squibb63.4318.6241.54%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts